In recent years, the emergence of carbapenem-resistant strains has been increasing worldwide, including in Romania. Rapid tests for post-mortem examinations have been researched and currently have several applications. In the present study, we aimed to test the performance of O.K.N.V.I. RESIST-5 tests on impure post-mortem biological samples compared with a standard of pure cultures. When a death occurs during hospitalization and the issue of malpractice arises, the medico-legal practice would benefit from rapid tests applicable to post-mortem samples. Thus, detection and differentiation of the five targeted carbapenemases, namely oxacilinase-48, Klebsiella pneumoniae carbapenemase, New Delhi metallo-β-lactamase, Verona integron-encoded metallo-β-lactamase and imipenemase, could be useful in guiding sampling for third-party microbiological assessment and could also be an asset from an epidemiological standpoint. The present prospective and observational pilot study included medico-legal autopsy cases performed at Mina Minovici National Institute of Legal Medicine (Romania) between June and July 2022. A total of two sets of O.K.N.V.I. RESIST-5 tests were performed: Test I, which was performed on-site from biological samples obtained during autopsy; and Test II, which was performed on pure cultures after sample inoculation and incubation. Total of 39 O.K.N.V.I. RESIST-5 rapid tests were performed on 19 biological samples, at least one sample per case. The O.K.N.V.I. RESIST-5 tests performed on-site showed an overall sensitivity of 92.3% with a 100% specificity. The results obtained through rapid tests using post-mortem impure samples were comparable to the results obtained from sample cultures with good sensitivity and specificity. Through post-mortem screening for carbapenem resistance, it would be possible to narrow down the number of cases that require further bacteriological assessment.
近年来，对碳青霉烯类耐药菌株的出现在全球范围内日益增多，罗马尼亚也不例外。用于尸检的快速检测方法已得到研究，目前已有多种应用。在本研究中，我们的目的是测试 O.K.N.V.I. RESIST-5 检验法与纯培养物标准相比在不纯的死后生物样本上的性能。当死亡发生在住院期间，出现渎职问题时，适用于死后样本的快速检测将使医学法律实践受益匪浅。因此，检测和区分五种目标碳青霉烯酶（即氧西林酶-48、肺炎克雷伯氏菌碳青霉烯酶、新德里金属-β-内酰胺酶、维罗纳整合子编码的金属-β-内酰胺酶和亚胺培南酶）可用于指导第三方微生物评估的采样，从流行病学的角度来看也是一种资产。本前瞻性观察试点研究包括 2022 年 6 月至 7 月期间在 Mina Minovici 国立法医学院（罗马尼亚）进行的法医尸检病例。共进行了两组O.K.N.V.I. RESIST-5测试：测试 I 是在解剖过程中获得的生物样本现场进行的；测试 II 是在样本接种和培养后对纯培养物进行的。共对 19 份生物样本进行了 39 次 O.K.N.V.I. RESIST-5 快速检测，每个病例至少检测一份样本。现场进行的 O.K.N.V.I. RESIST-5 测试显示，总体灵敏度为 92.3%，特异性为 100%。使用死后不纯样本进行快速检测所获得的结果与样本培养所获得的结果相当，具有良好的灵敏度和特异性。通过死后碳青霉烯耐药性筛查，可以缩小需要进一步细菌学评估的病例数量。
{"title":"Assessing O.K.N.V.I. RESIST‑5 performance for post‑mortem biological samples: A prospective pilot study.","authors":"Iuliana Diac, Lavinia Neculai-Cândea, Mihaela Horumbă, Cătălin Dogăroiu, Mihnea Costescu, Arthur-Atilla Keresztesi","doi":"10.3892/etm.2023.12302","DOIUrl":"https://doi.org/10.3892/etm.2023.12302","url":null,"abstract":"In recent years, the emergence of carbapenem-resistant strains has been increasing worldwide, including in Romania. Rapid tests for post-mortem examinations have been researched and currently have several applications. In the present study, we aimed to test the performance of O.K.N.V.I. RESIST-5 tests on impure post-mortem biological samples compared with a standard of pure cultures. When a death occurs during hospitalization and the issue of malpractice arises, the medico-legal practice would benefit from rapid tests applicable to post-mortem samples. Thus, detection and differentiation of the five targeted carbapenemases, namely oxacilinase-48, <i>Klebsiella pneumoniae</i> carbapenemase, New Delhi metallo-β-lactamase, Verona integron-encoded metallo-β-lactamase and imipenemase, could be useful in guiding sampling for third-party microbiological assessment and could also be an asset from an epidemiological standpoint. The present prospective and observational pilot study included medico-legal autopsy cases performed at Mina Minovici National Institute of Legal Medicine (Romania) between June and July 2022. A total of two sets of O.K.N.V.I. RESIST-5 tests were performed: Test I, which was performed on-site from biological samples obtained during autopsy; and Test II, which was performed on pure cultures after sample inoculation and incubation. Total of 39 O.K.N.V.I. RESIST-5 rapid tests were performed on 19 biological samples, at least one sample per case. The O.K.N.V.I. RESIST-5 tests performed on-site showed an overall sensitivity of 92.3% with a 100% specificity. The results obtained through rapid tests using post-mortem impure samples were comparable to the results obtained from sample cultures with good sensitivity and specificity. Through post-mortem screening for carbapenem resistance, it would be possible to narrow down the number of cases that require further bacteriological assessment.","PeriodicalId":12285,"journal":{"name":"Experimental and therapeutic medicine","volume":"73 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138825953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sagittal split ramus osteotomy (SSRO) is a widely performed orthognathic surgery; however, among the various reported complications of SSRO, pseudoaneurysms are rarely reported. Pseudoaneurysms are rare vascular lesions formed by damage to the arterial wall that can occur after trauma or postoperatively, causing uncontrolled bleeding. The present report describes a case of a pseudoaneurysm that occurred after SSRO in a 22‑year‑old female patient. Le Fort I osteotomy and bilateral SSRO were performed under general anesthesia to improve the gummy smile and mandibular asymmetry of the patient. While osteotomizing the medial side of the left SSRO, major bleeding occurred from the soft tissue of the posterior margin of the mandibular branch. Direct compression with gauze and a local hemostatic agent stopped the bleeding. Immediately after returning to the ward, bleeding was observed from the left wound site and marked swelling of the left buccal area occurred. Contrast‑enhanced computed tomography revealed a pseudoaneurysm of the left superficial temporal artery (STA). Subsequently, arterial embolization for the pseudoaneurysm was performed. Overall, the present report describes a rare case of pseudoaneurysm of the STA as a postoperative complication of SSRO.
矢状分支截骨术(SSRO)是一种广泛应用的正颌手术;然而，在SSRO的各种并发症中，假性动脉瘤的报道很少。假性动脉瘤是一种罕见的由动脉壁损伤形成的血管病变，可在创伤后或术后发生，引起无法控制的出血。本报告描述了一个22岁的女性患者在SSRO后发生假性动脉瘤的病例。在全身麻醉下行Le Fort I型截骨术和双侧SSRO，以改善患者的牙龈微笑和下颌不对称。在左侧SSRO内侧截骨时，下颌骨分支后缘软组织发生大出血。直接用纱布和局部止血药压迫止血。返回病房后，立即发现左侧伤口出血，左侧颊区出现明显肿胀。增强计算机断层扫描显示左侧颞浅动脉(STA)假性动脉瘤。随后，对假性动脉瘤进行动脉栓塞。总的来说，本报告描述了一例罕见的STA假性动脉瘤作为SSRO的术后并发症。
{"title":"Pseudoaneurysm of the superficial temporal artery after sagittal split ramus osteotomy: A case report","authors":"Tomoki Kato, Takeshi Yoshida, Yasuyuki Onishi, Takuma Watanabe, Shigeki Yamanaka, Shizuko Fukuhara, Kazumasa Nakao","doi":"10.3892/etm.2023.12301","DOIUrl":"https://doi.org/10.3892/etm.2023.12301","url":null,"abstract":"Sagittal split ramus osteotomy (SSRO) is a widely performed orthognathic surgery; however, among the various reported complications of SSRO, pseudoaneurysms are rarely reported. Pseudoaneurysms are rare vascular lesions formed by damage to the arterial wall that can occur after trauma or postoperatively, causing uncontrolled bleeding. The present report describes a case of a pseudoaneurysm that occurred after SSRO in a 22‑year‑old female patient. Le Fort I osteotomy and bilateral SSRO were performed under general anesthesia to improve the gummy smile and mandibular asymmetry of the patient. While osteotomizing the medial side of the left SSRO, major bleeding occurred from the soft tissue of the posterior margin of the mandibular branch. Direct compression with gauze and a local hemostatic agent stopped the bleeding. Immediately after returning to the ward, bleeding was observed from the left wound site and marked swelling of the left buccal area occurred. Contrast‑enhanced computed tomography revealed a pseudoaneurysm of the left superficial temporal artery (STA). Subsequently, arterial embolization for the pseudoaneurysm was performed. Overall, the present report describes a rare case of pseudoaneurysm of the STA as a postoperative complication of SSRO.","PeriodicalId":12285,"journal":{"name":"Experimental and therapeutic medicine","volume":"9 10","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134992148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Any Axelerad, Lavinia Muja, Cristina Mihai, Alina Stuparu, Anca Gogu, Dragos Jianu, Corina Frecus, Silviu Axelerad, Silvia Petrov, Carmen Sirbu, Simona Cambrea, Radu Baz, Florentina Ionita‑radu
The present study focused on examining the association between the SARS‑CoV‑2 virus, responsible for the COVID‑19 pandemic, and cerebral venous thrombosis (CVT), a specific form of stroke that affects the brain's vessels and sinuses. While COVID‑19 is primarily recognized for its respiratory impact, it may also affect other organs, including the brain. One notable aspect of COVID‑19 is its association with coagulopathy, an abnormal condition of blood clotting. Coagulopathy may result in various complications, including neurological ones such as stroke. The study analyzed data obtained from patients admitted to a neurology department who had confirmed neurological pathologies along with COVID‑19. It specifically examined the cases of three patients with neurological conditions and COVID‑19, discussing their risk factors and how their conditions progressed clinically. The study concluded that COVID‑19 infection increases the likelihood of stroke, particularly within the initial 10 days after infection. CVT in particular is strongly linked to COVID‑19 and its underlying mechanisms involve immune systemic processes, cytokine storms, increased blood thickness, thrombogenesis, hypercoagulability and inflammation. The presence of SARS‑CoV‑2 infection may worsen the procoagulant cascade, thereby affecting the clinical condition of patients with CVT. The study underscores the importance of recognizing this uncommon but treatable consequence of COVID‑19 infection. Furthermore, it highlights the uniqueness of the study in evaluating COVID‑19 infection in patients with CVT from Romania and South‑East Europe. The findings support the existence of neurological disorders, including clotting complications in the brain's sinuses and vessels, in individuals infected with SARS‑CoV‑2. Several risk factors contribute to the development of CVT, such as infections, oral contraceptives, pregnancy, hematological disorders, trauma, autoimmune disorders and malignancies.
{"title":"SARS‑CoV‑2 infection and associated risk factors for clinical cases of cerebral venous thrombosis: A case series","authors":"Any Axelerad, Lavinia Muja, Cristina Mihai, Alina Stuparu, Anca Gogu, Dragos Jianu, Corina Frecus, Silviu Axelerad, Silvia Petrov, Carmen Sirbu, Simona Cambrea, Radu Baz, Florentina Ionita‑radu","doi":"10.3892/etm.2023.12300","DOIUrl":"https://doi.org/10.3892/etm.2023.12300","url":null,"abstract":"The present study focused on examining the association between the SARS‑CoV‑2 virus, responsible for the COVID‑19 pandemic, and cerebral venous thrombosis (CVT), a specific form of stroke that affects the brain's vessels and sinuses. While COVID‑19 is primarily recognized for its respiratory impact, it may also affect other organs, including the brain. One notable aspect of COVID‑19 is its association with coagulopathy, an abnormal condition of blood clotting. Coagulopathy may result in various complications, including neurological ones such as stroke. The study analyzed data obtained from patients admitted to a neurology department who had confirmed neurological pathologies along with COVID‑19. It specifically examined the cases of three patients with neurological conditions and COVID‑19, discussing their risk factors and how their conditions progressed clinically. The study concluded that COVID‑19 infection increases the likelihood of stroke, particularly within the initial 10 days after infection. CVT in particular is strongly linked to COVID‑19 and its underlying mechanisms involve immune systemic processes, cytokine storms, increased blood thickness, thrombogenesis, hypercoagulability and inflammation. The presence of SARS‑CoV‑2 infection may worsen the procoagulant cascade, thereby affecting the clinical condition of patients with CVT. The study underscores the importance of recognizing this uncommon but treatable consequence of COVID‑19 infection. Furthermore, it highlights the uniqueness of the study in evaluating COVID‑19 infection in patients with CVT from Romania and South‑East Europe. The findings support the existence of neurological disorders, including clotting complications in the brain's sinuses and vessels, in individuals infected with SARS‑CoV‑2. Several risk factors contribute to the development of CVT, such as infections, oral contraceptives, pregnancy, hematological disorders, trauma, autoimmune disorders and malignancies.","PeriodicalId":12285,"journal":{"name":"Experimental and therapeutic medicine","volume":"47 12","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134901885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bilateral uterine artery ligation (BUAL) serves as an effective surgical devascularization procedure in obstetric emergencies. However, concerns regarding the impact of uterine devascularization have evoked dispute. Here, the fetal growth index and obstetrical outcomes during the subsequent pregnancy of women who had undergone BUAL during cesarean section are reported. The case series of women who underwent BUAL during cesarean section and had another delivery later at the Xiamen Women and Children's Hospital between 2011 and 2020 is described. Pregnancies that did not continue beyond 20 weeks of gestation were excluded. Cases were identified from neonatal and obstetric databases and the clinical data of all cases were extracted. A total of 12 cases were identified retrospectively. Fetal biometric parameters of subsequent pregnancies in all cases including biparietal diameter, head circumference, abdominal circumference, and femur length are presented graphically across the different gestational ages and were all within the range of the 3rd‑97th percentile. No maternal or neonatal morbidity was observed. BUAL did not appear to compromise a woman's subsequent obstetric outcomes. As a safe and simple surgical technique, it is safe to recommend BUAL in clinical practice.
{"title":"Subsequent pregnancy in women who have undergone bilateral uterine artery ligation during cesarean section: A case series","authors":"Jian An","doi":"10.3892/etm.2023.12296","DOIUrl":"https://doi.org/10.3892/etm.2023.12296","url":null,"abstract":"Bilateral uterine artery ligation (BUAL) serves as an effective surgical devascularization procedure in obstetric emergencies. However, concerns regarding the impact of uterine devascularization have evoked dispute. Here, the fetal growth index and obstetrical outcomes during the subsequent pregnancy of women who had undergone BUAL during cesarean section are reported. The case series of women who underwent BUAL during cesarean section and had another delivery later at the Xiamen Women and Children's Hospital between 2011 and 2020 is described. Pregnancies that did not continue beyond 20 weeks of gestation were excluded. Cases were identified from neonatal and obstetric databases and the clinical data of all cases were extracted. A total of 12 cases were identified retrospectively. Fetal biometric parameters of subsequent pregnancies in all cases including biparietal diameter, head circumference, abdominal circumference, and femur length are presented graphically across the different gestational ages and were all within the range of the 3rd‑97th percentile. No maternal or neonatal morbidity was observed. BUAL did not appear to compromise a woman's subsequent obstetric outcomes. As a safe and simple surgical technique, it is safe to recommend BUAL in clinical practice.","PeriodicalId":12285,"journal":{"name":"Experimental and therapeutic medicine","volume":"75 7","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136346268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Following the publication of this paper, it was drawn to the Editors’ attention by a concerned reader that the western blotting data shown in Figs. 2 and 4, and the Transwell migration assay data in Fig. 3B, were strikingly similar to data appearing in different form in other articles written by different authors at different research institutes that had either already been published elsewhere prior to the submission of this paper to Experimental and Therapeutic Medicine, or were under consideration for publication at around the same time. In view of the fact that these data had already apparently been published previously, the Editor of Experimental and Therapeutic Medicine has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Experimental and Therapeutic Medicine 6: 899‑903, 2013; 10.3892/etm.2013.1265]
{"title":"[Retracted] Rosuvastatin suppresses platelet‑derived growth factor‑BB‑induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway","authors":"Jianting Gan, Ping Li, Zhengdong Wang, Jian Chen, Xiangwen Liang, Ming Liu, Wenchao Xie, Ruixing Yin, Feng Huang","doi":"10.3892/etm.2023.12299","DOIUrl":"https://doi.org/10.3892/etm.2023.12299","url":null,"abstract":"Following the publication of this paper, it was drawn to the Editors’ attention by a concerned reader that the western blotting data shown in Figs. 2 and 4, and the Transwell migration assay data in Fig. 3B, were strikingly similar to data appearing in different form in other articles written by different authors at different research institutes that had either already been published elsewhere prior to the submission of this paper to <em>Experimental and Therapeutic Medicine</em>, or were under consideration for publication at around the same time. In view of the fact that these data had already apparently been published previously, the Editor of <em>Experimental and Therapeutic Medicine</em> has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Experimental and Therapeutic Medicine 6: 899‑903, 2013; 10.3892/etm.2013.1265]<br />","PeriodicalId":12285,"journal":{"name":"Experimental and therapeutic medicine","volume":"86 7","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136346807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Genitourinary symptoms of menopause (GSM) affect ~50% of women after menopause. Recently, CO2 laser therapy has been used for managing GSM but without high quality evidence. The present review assessed the effectiveness of CO2 laser therapy in the management of GSM. PubMed, Embase, Web of Science, CENTRAL and Scopus databases were searched for randomized controlled trials (RCTs), published up to June 30, 2023, comparing CO2 laser and sham laser treatments for GSM management. The outcomes of interest included Female Sexual Function Index (FSFI), Vaginal Health Index (VHI) and visual analog scale (VAS) for dyspareunia, dryness, burning, itching and dysuria. A total of seven RCTs were included in the review and meta‑analysis, with 6/7 studies using three sessions of laser therapy, 4‑8 weeks apart. Meta‑analysis demonstrated no statistically significant difference in FSFI [mean difference (MD), ‑1.48; 95% CI, ‑5.85, 2.89; I2=45%] and VHI scores (MD, ‑0.18; 95% CI, ‑1.66, 1.31; I2 =72%) between laser and control groups. Meta‑analysis also demonstrated no statistically significant difference in VAS scores for dyspareunia (MD, ‑1.63; 95% CI; ‑4.06, 0.80; I2=91%), dryness (MD, ‑1.30; 95% CI, ‑3.14, 0.53; I2=75%), burning (MD, ‑0.76; 95% CI, ‑2.03; 0.51 I2=56%), itching (MD, ‑0.28; 95% CI, ‑0.95, 0.38; I2=0%) and dysuria (MD, 0.15; 95% CI, ‑0.37, 0.67; I2=23%) between the groups. The included RCTs had low risk of bias. In conclusion, meta‑analyses of high‑quality sham‑controlled RCTs indicated that CO2 may not have any beneficial effect on GSM. Limited data and high heterogeneity in meta‑analyses in this area of research are important limitations that need to be addressed by future RCTs.
{"title":"Carbon dioxide laser therapy for the management of genitourinary syndrome of menopause: A meta‑analysis of randomized controlled trials","authors":"Yihua Ni, Junyu Lian","doi":"10.3892/etm.2023.12297","DOIUrl":"https://doi.org/10.3892/etm.2023.12297","url":null,"abstract":"Genitourinary symptoms of menopause (GSM) affect ~50% of women after menopause. Recently, CO<sub>2</sub> laser therapy has been used for managing GSM but without high quality evidence. The present review assessed the effectiveness of CO<sub>2</sub> laser therapy in the management of GSM. PubMed, Embase, Web of Science, CENTRAL and Scopus databases were searched for randomized controlled trials (RCTs), published up to June 30, 2023, comparing CO<sub>2</sub> laser and sham laser treatments for GSM management. The outcomes of interest included Female Sexual Function Index (FSFI), Vaginal Health Index (VHI) and visual analog scale (VAS) for dyspareunia, dryness, burning, itching and dysuria. A total of seven RCTs were included in the review and meta‑analysis, with 6/7 studies using three sessions of laser therapy, 4‑8 weeks apart. Meta‑analysis demonstrated no statistically significant difference in FSFI [mean difference (MD), ‑1.48; 95% CI, ‑5.85, 2.89; I<sup>2</sup>=45%] and VHI scores (MD, ‑0.18; 95% CI, ‑1.66, 1.31; I<sup>2</sup> =72%) between laser and control groups. Meta‑analysis also demonstrated no statistically significant difference in VAS scores for dyspareunia (MD, ‑1.63; 95% CI; ‑4.06, 0.80; I2=91%), dryness (MD, ‑1.30; 95% CI, ‑3.14, 0.53; I<sup>2</sup>=75%), burning (MD, ‑0.76; 95% CI, ‑2.03; 0.51 I<sup>2</sup>=56%), itching (MD, ‑0.28; 95% CI, ‑0.95, 0.38; I<sup>2</sup>=0%) and dysuria (MD, 0.15; 95% CI, ‑0.37, 0.67; I<sup>2</sup>=23%) between the groups. The included RCTs had low risk of bias. In conclusion, meta‑analyses of high‑quality sham‑controlled RCTs indicated that CO<sub>2</sub> may not have any beneficial effect on GSM. Limited data and high heterogeneity in meta‑analyses in this area of research are important limitations that need to be addressed by future RCTs.","PeriodicalId":12285,"journal":{"name":"Experimental and therapeutic medicine","volume":"42 7","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Butorphanol is a synthetic selective opioid receptor antagonist that exhibits substantial analgesic effects. The present study aimed to explore the effects of butorphanol on a neurodegenerative disease cell model and to investigate its specific regulatory mechanism. Cell viability of PC12 cells was assessed using the Cell Counting Kit‑8 assay. Oxidative stress levels were measured by the corresponding kits and western blotting of specific protein markers. Apoptosis was determined using the terminal‑deoxynucleoitidyl transferase mediated nick end labeling assay and by western blotting. Western blotting was used to analyze the expression levels of c‑Jun NH2‑terminal kinase (JNK)/p38 signaling pathway‑related proteins. Thiobarbituric acid‑reactive substances and Fe+2 content were detected using the corresponding assay kits and the expression levels of ferroptosis‑associated proteins were assessed by western blotting following the addition of the JNK activator anisomycin (ANI). Oxidative stress and apoptosis were examined with the aforementioned assays following the supplementation of ANI or the ferroptosis inducer erastin (ERA). It was revealed that butorphanol dose‑dependently enhanced the viability and suppressed the oxidative stress and apoptosis of H2O2‑treated PC12 cells. In addition, butorphanol blocked JNK/p38 signaling and hampered ferroptosis, while this effect was reversed by ANI. ANI or ERA reversed the effects of butorphanol on oxidative stress and apoptosis of H2O2‑treated PC12 cells. In summary, butorphanol suppressed ferroptosis by blocking JNK/p38 signaling to impart inhibitory effects on oxidative stress and apoptosis in a neurodegenerative disease cell model.
丁托啡诺是一种合成选择性阿片受体拮抗剂，具有明显的镇痛作用。本研究旨在探讨丁托啡诺对神经退行性疾病细胞模型的影响，并探讨其具体的调控机制。使用细胞计数试剂盒- 8检测评估PC12细胞的细胞活力。采用相应试剂盒和特异性蛋白标记物的western blotting检测氧化应激水平。采用末端脱氧核苷转移酶介导的缺口末端标记法和western blotting检测细胞凋亡。Western blotting分析c - Jun NH2末端激酶(JNK)/p38信号通路相关蛋白的表达水平。使用相应的检测试剂盒检测硫代巴比妥酸反应物质和Fe+2含量，在添加JNK激活剂大霉素(ANI)后，通过western blotting评估铁下垂相关蛋白的表达水平。在补充ANI或铁下垂诱导剂erastin (ERA)后，用上述实验检测氧化应激和细胞凋亡。结果表明，丁托啡诺能剂量依赖性地增强H2O2处理的PC12细胞活力，抑制氧化应激和凋亡。此外，butorphanol阻断JNK/p38信号传导并抑制铁下垂，而ANI可逆转这一作用。ANI或ERA逆转了丁托啡诺对H2O2处理的PC12细胞氧化应激和凋亡的影响。综上所述，在神经退行性疾病细胞模型中，butorphanol通过阻断JNK/p38信号传导抑制铁凋亡，从而对氧化应激和细胞凋亡产生抑制作用。
{"title":"Butorphanol inhibits ferroptosis to attenuate PC12 cell injury by blocking JNK/p38 signaling","authors":"Lulu Ji, Qing She, Ping Zhou, Yibin Qin","doi":"10.3892/etm.2023.12295","DOIUrl":"https://doi.org/10.3892/etm.2023.12295","url":null,"abstract":"Butorphanol is a synthetic selective opioid receptor antagonist that exhibits substantial analgesic effects. The present study aimed to explore the effects of butorphanol on a neurodegenerative disease cell model and to investigate its specific regulatory mechanism. Cell viability of PC12 cells was assessed using the Cell Counting Kit‑8 assay. Oxidative stress levels were measured by the corresponding kits and western blotting of specific protein markers. Apoptosis was determined using the terminal‑deoxynucleoitidyl transferase mediated nick end labeling assay and by western blotting. Western blotting was used to analyze the expression levels of c‑Jun NH2‑terminal kinase (JNK)/p38 signaling pathway‑related proteins. Thiobarbituric acid‑reactive substances and Fe<sup>+2</sup> content were detected using the corresponding assay kits and the expression levels of ferroptosis‑associated proteins were assessed by western blotting following the addition of the JNK activator anisomycin (ANI). Oxidative stress and apoptosis were examined with the aforementioned assays following the supplementation of ANI or the ferroptosis inducer erastin (ERA). It was revealed that butorphanol dose‑dependently enhanced the viability and suppressed the oxidative stress and apoptosis of H<sub>2</sub>O<sub>2</sub>‑treated PC12 cells. In addition, butorphanol blocked JNK/p38 signaling and hampered ferroptosis, while this effect was reversed by ANI. ANI or ERA reversed the effects of butorphanol on oxidative stress and apoptosis of H<sub>2</sub>O<sub>2</sub>‑treated PC12 cells. In summary, butorphanol suppressed ferroptosis by blocking JNK/p38 signaling to impart inhibitory effects on oxidative stress and apoptosis in a neurodegenerative disease cell model.","PeriodicalId":12285,"journal":{"name":"Experimental and therapeutic medicine","volume":"108 36","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135137105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Epstein‑Barr virus (EBV) has been implicated in the development of a wide range of lymphoproliferative disorders. In this process, the role of programmed cell death 1 (PD‑1)/programmed cell death ligand 1 (PD‑L1) has remained to be clarified. A meta‑analysis of 20 studies was performed and risk ratios (RRs) with 95% confidence intervals (CIs) were used to evaluate the association between PD‑L1/PD‑1 expression and the status of EBV infection. The results showed that the expression level of PD‑L1 in tumor cells was significantly higher in EBV+ cases with a pooled RR of 2.26 (95% CI, 1.63‑3.14; P<0.01), particularly in subtypes of diffuse large B‑cell lymphoma (DLBCL) and classical Hodgkin lymphoma. Similarly, EBV infection increased the expression of PD‑L1 in immune cells with a pooled RR of 2.20 (95% CI, 1.55‑3.12; P<0.01). In subtypes of DLBCL and post‑transplant lymphoproliferative disorder, the expression of PD‑L1 in immune cells is increased in EBV+ cases. Regarding the expression level of PD‑1 in tumor‑infiltrating lymphocytes (TILs), no significance was found between EBV infection and PD‑1 expression, with a pooled RR of 1.10 (95% CI, 0.81‑1.48; P>0.05). The present meta‑analysis demonstrated that in EBV‑associated lymphoproliferative disorders, EBV infection was associated with the expression level of PD‑L1 in tumor cells and immune cells but was not associated with the expression of PD‑1 in TILs.
{"title":"Expression of the immune checkpoint molecules PD‑L1 and PD‑1 in EBV‑associated lymphoproliferative disorders: A meta‑analysis","authors":"Junyao Yu, Shenhe Jin, Xiufeng Yin, Huaping Du","doi":"10.3892/etm.2023.12294","DOIUrl":"https://doi.org/10.3892/etm.2023.12294","url":null,"abstract":"Epstein‑Barr virus (EBV) has been implicated in the development of a wide range of lymphoproliferative disorders. In this process, the role of programmed cell death 1 (PD‑1)/programmed cell death ligand 1 (PD‑L1) has remained to be clarified. A meta‑analysis of 20 studies was performed and risk ratios (RRs) with 95% confidence intervals (CIs) were used to evaluate the association between PD‑L1/PD‑1 expression and the status of EBV infection. The results showed that the expression level of PD‑L1 in tumor cells was significantly higher in EBV+ cases with a pooled RR of 2.26 (95% CI, 1.63‑3.14; P<0.01), particularly in subtypes of diffuse large B‑cell lymphoma (DLBCL) and classical Hodgkin lymphoma. Similarly, EBV infection increased the expression of PD‑L1 in immune cells with a pooled RR of 2.20 (95% CI, 1.55‑3.12; P<0.01). In subtypes of DLBCL and post‑transplant lymphoproliferative disorder, the expression of PD‑L1 in immune cells is increased in EBV+ cases. Regarding the expression level of PD‑1 in tumor‑infiltrating lymphocytes (TILs), no significance was found between EBV infection and PD‑1 expression, with a pooled RR of 1.10 (95% CI, 0.81‑1.48; P>0.05). The present meta‑analysis demonstrated that in EBV‑associated lymphoproliferative disorders, EBV infection was associated with the expression level of PD‑L1 in tumor cells and immune cells but was not associated with the expression of PD‑1 in TILs.","PeriodicalId":12285,"journal":{"name":"Experimental and therapeutic medicine","volume":"117 21","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135137898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The imbalance in immune homeostasis plays a crucial role in the pathogenesis of myasthenia gravis (MG). MicroRNAs (miRs) have been identified as key regulators of immune homeostasis. B‑cell lymphoma/leukemia 10 (BCL10) has been implicated in the activation and suppressive function of regulatory T cells (Tregs). This study aimed to investigate the potential role of miR‑155‑5p in modulating the activation and function of Tregs in MG. To achieve this objective, blood samples were collected from MG patients to assess the expression levels of miR‑155‑5p and BCL10, as well as the proportion of circulating Tregs, in comparison to healthy controls. The correlation between miR‑155‑5p and BCL10 levels was evaluated in human samples. The expression levels of miR‑155‑5p and the numbers of circulating Tregs were also examined in an animal model of experimental autoimmune MG (EAMG). A dual‑luciferase reporter assay was used to verify whether miR‑155‑5p can target BCL10. To determine the regulatory function of BCL10 in Tregs, CD4+ CD25+ Tregs were transfected with either small interfering‑BCL10 or miR‑155‑5p inhibitor, and the expression levels of the anti‑inflammatory cytokine IL‑10 and transcription factors Foxp3, TGF‑β1, CTLA4, and ICOS were measured. The results demonstrated that the expression level of miR‑155‑5p was significantly higher in patients with MG compared with that in healthy controls, whereas the expression level of BCL10 was significantly decreased in patients with MG. Furthermore, there was a significant negative correlation between the expression levels of miR‑155‑5p and BCL10. The number of circulating Tregs was significantly reduced in patients with MG and in the spleen of rats with EAMG compared with that in the corresponding control groups. The dual‑luciferase reporter assay demonstrated that miR‑155‑5p could target BCL10. The Tregs transfected with si‑BCL10 demonstrated significant decreases in the protein levels of TGF‑β1 and IL‑10, as well as in the mRNA expression levels of Foxp3, TGF‑β1, CTLA‑4 and ICOS. Conversely, the Tregs transfected with the miR‑155‑5p inhibitor exhibited a substantial increase in these protein and mRNA expression levels compared with their respective control groups. Furthermore, the knockdown of BCL10 exhibited a decline in the suppressive efficacy of Tregs on the proliferation of CD4+ T cells. Conversely, the suppression of miR‑155‑5p expression attenuated the inhibition of the BCL10 gene, potentially causing an indirect influence on the suppressive capability of Tregs on the proliferation of CD4+ T cells. BCL10 was thus found to contribute to the activation and immunosuppressive function of Tregs. In summary, the present study demonstrated that miR‑155‑5p inhibited the activation and immunosuppressive function of Tregs by targeting BCL10, which may be used as a future potential target for the treatment of MG.
{"title":"MicroRNA‑155‑5p affects regulatory T cell activation and immunosuppressive function by targeting BCL10 in myasthenia gravis","authors":"Jing Sun, Mengjiao Sun, Xiaoling Li, Qinfang Xie, Wenjing Zhang, Manxia Wang","doi":"10.3892/etm.2023.12293","DOIUrl":"https://doi.org/10.3892/etm.2023.12293","url":null,"abstract":"The imbalance in immune homeostasis plays a crucial role in the pathogenesis of myasthenia gravis (MG). MicroRNAs (miRs) have been identified as key regulators of immune homeostasis. B‑cell lymphoma/leukemia 10 (BCL10) has been implicated in the activation and suppressive function of regulatory T cells (Tregs). This study aimed to investigate the potential role of miR‑155‑5p in modulating the activation and function of Tregs in MG. To achieve this objective, blood samples were collected from MG patients to assess the expression levels of miR‑155‑5p and BCL10, as well as the proportion of circulating Tregs, in comparison to healthy controls. The correlation between miR‑155‑5p and BCL10 levels was evaluated in human samples. The expression levels of miR‑155‑5p and the numbers of circulating Tregs were also examined in an animal model of experimental autoimmune MG (EAMG). A dual‑luciferase reporter assay was used to verify whether miR‑155‑5p can target BCL10. To determine the regulatory function of BCL10 in Tregs, CD4+ CD25+ Tregs were transfected with either small interfering‑BCL10 or miR‑155‑5p inhibitor, and the expression levels of the anti‑inflammatory cytokine IL‑10 and transcription factors Foxp3, TGF‑β1, CTLA4, and ICOS were measured. The results demonstrated that the expression level of miR‑155‑5p was significantly higher in patients with MG compared with that in healthy controls, whereas the expression level of BCL10 was significantly decreased in patients with MG. Furthermore, there was a significant negative correlation between the expression levels of miR‑155‑5p and BCL10. The number of circulating Tregs was significantly reduced in patients with MG and in the spleen of rats with EAMG compared with that in the corresponding control groups. The dual‑luciferase reporter assay demonstrated that miR‑155‑5p could target BCL10. The Tregs transfected with si‑BCL10 demonstrated significant decreases in the protein levels of TGF‑β1 and IL‑10, as well as in the mRNA expression levels of Foxp3, TGF‑β1, CTLA‑4 and ICOS. Conversely, the Tregs transfected with the miR‑155‑5p inhibitor exhibited a substantial increase in these protein and mRNA expression levels compared with their respective control groups. Furthermore, the knockdown of BCL10 exhibited a decline in the suppressive efficacy of Tregs on the proliferation of CD4<sup>+</sup> T cells. Conversely, the suppression of miR‑155‑5p expression attenuated the inhibition of the BCL10 gene, potentially causing an indirect influence on the suppressive capability of Tregs on the proliferation of CD4<sup>+</sup> T cells. BCL10 was thus found to contribute to the activation and immunosuppressive function of Tregs. In summary, the present study demonstrated that miR‑155‑5p inhibited the activation and immunosuppressive function of Tregs by targeting BCL10, which may be used as a future potential target for the treatment of MG.","PeriodicalId":12285,"journal":{"name":"Experimental and therapeutic medicine","volume":" 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135242352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A prolonged second stage of vaginal delivery increases the risk of shoulder dystocia, unnecessary episiotomies and cesarean sections. However, no standardized method has been proposed to tackle this issue. The effects of pelvic floor myofascial manipulation intervention during the second stage of labor in primiparas and its prognostic value in neonatal postpartum outcomes remain unknown. In the present study, a total of 60 primiparas who were expecting a vaginal delivery in the Second Affiliated Hospital of Hainan Medical College (Haikou, China) between October 2021 and January 2022 were selected. These women were randomly assigned to a control group (standard intrapartum care) or an experimental group (pelvic floor myofascial manipulation for 15‑20 min during the second stage of labor along with standard intrapartum care) using a random number table, with 28 patients in each group. There was no significant difference in age, gestational time or body mass index between the two groups before delivery, indicating that the baseline data were comparable. The second stage of labor duration, forced breath‑holding time and postpartum hemorrhage volume in the experimental group were significantly lower than those in the control group. The pain visual analog scale scores, fatigue scores and neonatal Apgar scores in the experimental group were also significantly lower than those in the control group. The rate of episiotomy in the experimental group was lower than that in the control group, but the difference was not statistically significant. In conclusion, pelvic floor myofascial manipulation intervention during the second stage of labor for primiparas with vaginal delivery can reduce the duration of the second stage of labor, the amount of bleeding during labor and the pain during labor. Meanwhile, it has the potential to improve neonatal outcomes.
{"title":"Effects of pelvic floor myofascial manipulation intervention on primiparas and neonates during the second stage of vaginal delivery","authors":"Yan-Qing Chen, Zhao-Wei Wang, Hai-Chao Liu, Jiao Wu, Jun-Zhong Qin, Ju-Hui Li, Dong-Qing Wu, Hui-Yu Jiang","doi":"10.3892/etm.2023.12292","DOIUrl":"https://doi.org/10.3892/etm.2023.12292","url":null,"abstract":"A prolonged second stage of vaginal delivery increases the risk of shoulder dystocia, unnecessary episiotomies and cesarean sections. However, no standardized method has been proposed to tackle this issue. The effects of pelvic floor myofascial manipulation intervention during the second stage of labor in primiparas and its prognostic value in neonatal postpartum outcomes remain unknown. In the present study, a total of 60 primiparas who were expecting a vaginal delivery in the Second Affiliated Hospital of Hainan Medical College (Haikou, China) between October 2021 and January 2022 were selected. These women were randomly assigned to a control group (standard intrapartum care) or an experimental group (pelvic floor myofascial manipulation for 15‑20 min during the second stage of labor along with standard intrapartum care) using a random number table, with 28 patients in each group. There was no significant difference in age, gestational time or body mass index between the two groups before delivery, indicating that the baseline data were comparable. The second stage of labor duration, forced breath‑holding time and postpartum hemorrhage volume in the experimental group were significantly lower than those in the control group. The pain visual analog scale scores, fatigue scores and neonatal Apgar scores in the experimental group were also significantly lower than those in the control group. The rate of episiotomy in the experimental group was lower than that in the control group, but the difference was not statistically significant. In conclusion, pelvic floor myofascial manipulation intervention during the second stage of labor for primiparas with vaginal delivery can reduce the duration of the second stage of labor, the amount of bleeding during labor and the pain during labor. Meanwhile, it has the potential to improve neonatal outcomes.","PeriodicalId":12285,"journal":{"name":"Experimental and therapeutic medicine","volume":"138 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135342504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：